Erenumab manufacturer drops bid for PBS listing

The CGRP anti-migraine prophylaxis drug erenumab (Aimovig) has had its application for listing on the PBS withdrawn by manufacturer Novartis. The company said it had decided not to proceed with a third erenumab submission to the Pharmaceutical Benefits Advisory Committee (PBAC) after being rejected twice for a listing for prevention of migraine It said erenumab ...

Already a member?

Login to keep reading.

© 2022 the limbic